Ultragenyx Pharmaceutical (NASDAQ: RARE) has recently received a number of price target changes and ratings updates:

  • 11/16/2017 – Ultragenyx Pharmaceutical was given a new $80.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/15/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 11/8/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
  • 11/5/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $76.00 price target on the stock. They wrote, “RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline.””
  • 11/3/2017 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Robert W. Baird from $85.00 to $80.00. They now have an “outperform” rating on the stock.
  • 10/25/2017 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
  • 10/6/2017 – Ultragenyx Pharmaceutical had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $71.00 price target on the stock, up previously from $69.00.

Ultragenyx Pharmaceutical Inc. (RARE) opened at $48.94 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $44.02 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same quarter in the previous year, the business earned ($1.64) earnings per share. The firm’s revenue was up 81.8% on a year-over-year basis. research analysts expect that Ultragenyx Pharmaceutical Inc. will post -7.26 earnings per share for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis purchased 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The purchase was disclosed in a filing with the SEC, which is available at this link. 9.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.